Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.89 +0.01 (+0.09%)
At close: Oct 1, 2026 · 4:00 PM EDT

Drugs Made In America Acquisition (DMAA) Preferred Stock Liabilities (2025 - 2026)

Updated

Drugs Made In America Acquisition (DMAA) recorded Preferred Stock Liabilities of $145.17 million in Q2 2026, down 38.3% from $235.16 million a year earlier.

Analysis

Drugs Made In America Acquisition (DMAA) Preferred Stock Liabilities (2025 - 2026) Analysis & Trends

At the end of FY2025, Drugs Made In America Acquisition reported Preferred Stock Liabilities of $239.91 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 BlackRock 164.13 Bn 110.49 Bn - -
2 Spdr Gold Trust 133.82 Bn -424.18 Bn - -
3 Blackstone 84.08 Bn 79.01 Bn - -
4 Brookfield 82.97 Bn -82.41 Bn 4.47 Bn -
5 Kkr 81.05 Bn 47.53 Bn - 3.07 Bn
6 Brookfield Asset Management 71.64 Bn 67.88 Bn - -
7 Apollo Global Management 65.67 Bn 3.35 Bn 10.56 Bn -
8 Wheaton Precious Metals 61.89 Bn 57.32 Bn 687.86 Mn -
9 Franco Nevada 46.13 Bn 43.49 Bn 451.00 Mn -
10 Drugs Made In America Acquisition 335.55 Mn 335.55 Mn - 145.17 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 145.17 Mn
Dec 31, 2025 239.91 Mn
Sep 30, 2025 237.60 Mn
Jun 30, 2025 235.16 Mn
Mar 31, 2025 232.74 Mn
API Access

Drugs Made In America Acquisition Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=DMAA&period=max&api_key=YOUR_API_KEY